Skip to main content
Biotage logo

Biotage — Investor Relations & Filings

Ticker · BIOT ISIN · SE0000454746 LEI · 529900SR87NBUKX74L58 ST Manufacturing
Open in API
Filings indexed 524 across all filing types
Latest filing 2025-02-21 Major Shareholding Noti…
Country SE Sweden
Listing ST BIOT

About Biotage

https://www.biotage.com/

Biotage is a global life science company specializing in separation and purification technologies. It provides systems, consumables, and intelligent workflow solutions for customers in drug discovery and development, analytical testing, and diagnostics. The company's portfolio supports a wide range of applications, including medicinal chemistry, peptide synthesis, biomolecule purification (proteins, DNA, oligonucleotides), and automated sample preparation. Key technologies are applied in flash chromatography and analytical testing for clinical, forensic, and environmental samples. Biotage focuses on streamlining laboratory processes to advance scientific research and human health.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding ('Innehavare' and 'Transaktionen') for an entity ('Handelsbanken Fonder AB') in a listed instrument ('Aktie SE0000454746'). Specifically, it shows the number of shares and voting rights before and after a 'Köp' (Purchase) transaction, crossing a threshold ('Gränsvärde för antal rösträtter' at 5%). This type of filing, reporting changes in significant share ownership that cross regulatory thresholds, corresponds to a Major Shareholding Notification. The Swedish context implies a filing similar to a Form 13F or Schedule 13D/G filing in the US, which maps best to the Major Shareholding Notification category (MRQ). The document is short and contains the full details, not just an announcement of a report.
2025-02-21 Swedish
Earnings Release 2024
Earnings Release Classification · 100% confidence The document is titled "Bokslutskommuniké januari – december 2024" (Year-end report communication January – December 2024) and contains detailed financial highlights for the fourth quarter (Q4) and the full year (January–December). It includes key metrics like Net Sales, EBITDA, Adjusted EBITDA, Operating Profit, Net Income, and Cash Flow, presented in a summary format typical of an earnings announcement. The presence of a CEO statement ("VD har ordet") and detailed financial tables/charts strongly suggests this is the initial release of the annual financial results, rather than the comprehensive 10-K filing itself. This aligns perfectly with the definition of an Earnings Release (ER). It is not a full 10-K because it is a 'kommuniké' (communication/release) summarizing the results, and it is not an RPA because it contains the actual results, not just an announcement that results are forthcoming. FY 2024
2025-02-19 Swedish
Audit Report / Information 2024
Audit Report / Information Classification · 98% confidence The document is explicitly titled "Year end Report January - December 2024" and contains detailed financial performance metrics for the fourth quarter (October - December) and the full year (January - December), including Net sales, EBITDA, Adjusted EBITDA, Operating profit, and Earnings per share. It also mentions the Board's proposal for the dividend to be presented at the upcoming Annual General Meeting. This structure and content are characteristic of a comprehensive annual financial report, which corresponds to the definition of an Annual Report (10-K), although this specific document might be a local equivalent or preliminary version, given the company name (Biotage AB (publ)) and SEK currency. Since the content is a full financial review for the year, 10-K is the most appropriate classification among the provided options for a comprehensive annual report. FY 2024
2025-02-19 English
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Biotage AB covering the period January to September 2024. It contains comprehensive financial statements, management commentary, and performance analysis for the third quarter and the nine-month period. It is not an announcement of a report, but the report itself, containing substantive financial data and analysis, thus fitting the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-10-23 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report January - September 2024' for Biotage AB. It contains comprehensive financial statements, including income statements, cash flow data, and detailed management commentary on performance for the nine-month period. It is not an announcement of a report, but the report itself, containing substantive financial data. Therefore, it fits the definition of an Interim/Quarterly Report. 9M 2024
2024-10-23 English
Major Shareholding Notification 2024
Major Shareholding Notification Classification · 100% confidence The document is a 'flaggningsmeddelande' (flagging notification) filed with the Swedish Financial Supervisory Authority (Finansinspektionen). It details a change in shareholding where Carnegie Fonder AB has crossed a 5% ownership threshold in Biotage AB. This type of disclosure regarding significant changes in share ownership is classified as a Major Shareholding Notification.
2024-10-11 Swedish

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.